RxDoctor Payments Data

Eric Robinson, MD

Cardiovascular Disease · Searcy, ARNPI 1962695668

Payments from drug & device makers

$2,674in general payments, 2019–2025

Across 115 payments — averaging $23.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Novartis$545
  • Amgen$258
  • Shockwave Medical, Inc$106
  • Irhythm Technologies, Inc.$79
  • Baxter Healthcare$72
  • plus $480 from 14 others

What the payments were for

  • Travel & lodging$37914%
  • Food & beverage$2,29586%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,674 in reported general payments places this provider in the 40th percentile of 130 cardiovascular disease providers in Arkansas.

See all cardiovascular disease providers in Arkansas

Medicare billing

Part B allowed, 2024
$234,789
Medicare patients
1,505
Services billed
4,228

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban814$607,903
XareltoRivaroxaban302$230,304
EntrestoSacubitril/Valsartan148$151,561
JardianceEmpagliflozin52$40,169
MultaqDronedarone Hcl32$32,907
Praluent PenAlirocumab39$31,789
Repatha SureclickEvolocumab25$22,112
Repatha PushtronexEvolocumab19$15,900
Ranolazine ErRanolazine100$11,533
Metoprolol Succinate946$10,342
CorlanorIvabradine Hcl13$5,755
Atorvastatin Calcium611$4,931
Varenicline Tartrate17$4,726
Carvedilol714$4,189
Isosorbide Mononitrate ErIsosorbide Mononitrate388$3,936

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$53$607,903814 claims
Johnson & JohnsonXarelto$29$230,304302 claims
NovartisEntresto$545$151,561148 claims
Sanofi-aventis U.S. LLCMultaq$28$32,90732 claims
AmgenCorlanor$258$5,75513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 130 cardiovascular disease providers in Arkansas.

Other cardiovascular disease in Searcy

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →